MedTrace Logo

Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure

NCT00811486 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-01-28

No results posted yet for this study

Summary

Secondary hyperaldosteronism and the non-osmotic release of arginine vasopressin (AVP) are the major factors in sodium and water retention in pulmonary arterial hypertension with right ventricular failure. Natriuretic doses of mineralocorticoid antagonist and aquaretic doses of V2 receptor antagonist will attenuate the sodium and water retention respectively, and be associated with clinical improvement.

Conditions

  • Right Heart Failure
  • Pulmonary Hypertension

Interventions

DRUG

Spironolactone and conivaptan

Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Shweta Bansal, MD · UCHSC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-07-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00811486 on ClinicalTrials.gov